{"id":"W4376613834","doi":"10.1016/j.esmoop.2023.101571","title":"LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"F. Hoffmann-La Roche; Eisai; Sanofi; Daiichi-Sankyo; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Internal medicine; Cyclophosphamide; Oncology; Adjuvant; Neoadjuvant therapy; Capecitabine; Placebo; Population; Breast cancer; Gastroenterology; Surgery; Chemotherapy; Cancer; Immunotherapy; Pathology; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003053415,0.002092156,0.002839937,0.0004313399,0.0004020396,0.001538999,0.001427809,0.001987244,0.01076054],"category_scores_gemma":[0.002815091,0.0007963094,0.003016595,0.0004520663,0.0008796938,0.0006717569,0.0006712628,0.003604482,0.002034817],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00106329,"about_ca_system_score_gemma":0.001679187,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001339921,"about_ca_topic_score_gemma":0.004080385,"domain_scores_codex":[0.9987147,0.0008762797,0.00004626686,0.0001307178,0.00007662195,0.0001553474],"domain_scores_gemma":[0.998849,0.0003100562,0.0002690467,0.0001033906,0.0001124054,0.0003560098],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9626213,0.00420845,0.0004217395,0.001162374,0.001515981,0.00004753101,0.00005408452,0.0004774281,0.007476221,0.0002649298,0.003592762,0.01815722],"study_design_scores_gemma":[0.9402457,0.0541326,0.001356797,0.00007103656,0.0007938598,0.00003652164,0.00001446174,0.0003651333,0.0005185683,0.000167391,0.002278995,0.00001873631],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8953912,0.016855,0.005763161,0.00507118,0.002641743,0.0280545,0.02456471,0.001178854,0.02047957],"genre_scores_gemma":[0.9276454,0.00453735,0.006967409,0.005749688,0.001048632,0.02119626,0.01415559,0.0002109219,0.01848873],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01076054,"threshold_uncertainty_score":0.03599763,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03329605026677972,"score_gpt":0.359875093027282,"score_spread":0.3265790427605023,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}